Literature DB >> 20419497

3D QSAR pharmacophore model based on diverse IKKβ inhibitors.

Shanthi Nagarajan1, Asif Ahmed, Hyunah Choo, Yong Seo Cho, Kwang-Seok Oh, Byung Ho Lee, Kye Jung Shin, Ae Nim Pae.   

Abstract

The inhibitor kappaB kinase β (IKKβ) is a serine-threonine protein kinase that is critically involved in the activation of the transcription factor nuclear factor kappa B (NF-κB) in response to various inflammatory stimuli. IKKβ-selective inhibitors could prove useful for the treatment of inflammatory diseases. In the absence of structural information, a ligand-based approach can serve as an alternative to the virtual screening of large databases. We have developed a 3D QSAR pharmacophore model based on 23 IKKβ inhibitors with 3 nM ≤ IC(50) ≤ 50000 nM. A four-feature pharmacophore containing a hydrophobic (Hy) feature, two ring aromatic (RA) features, and a hydrogen bond donor (D) feature was constructed. It yielded a correlation coefficient of 0.93 with experimentally determined activity data, and a correlation coefficient of 0.77 with training set activity data. The best hypothesis, Hypo 1, was validated by estimating the activities of 136 compounds in a test set. As well as the correlation analysis and test set activity estimation, a Fisher's validation test was conducted at the 95% confidence level. The pharmacophore model's specificity and selectivity were determined in an exhaustive enrichment study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419497     DOI: 10.1007/s00894-010-0714-8

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  16 in total

Review 1.  Activators and target genes of Rel/NF-kappaB transcription factors.

Authors:  H L Pahl
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.

Authors:  Andrew Baxter; Steve Brough; Anne Cooper; Eike Floettmann; Steve Foster; Christine Harding; Jason Kettle; Tom McInally; Craig Martin; Michelle Mobbs; Maurice Needham; Pete Newham; Stuart Paine; Steve St-Gallay; Sylvia Salter; John Unitt; Yafeng Xue
Journal:  Bioorg Med Chem Lett       Date:  2004-06-07       Impact factor: 2.823

Review 3.  IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges.

Authors:  Joann Strnad; James R Burke
Journal:  Trends Pharmacol Sci       Date:  2007-02-06       Impact factor: 14.819

4.  Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.

Authors:  Francis Beaulieu; Carl Ouellet; Edward H Ruediger; Makonen Belema; Yuping Qiu; Xuejie Yang; Jacques Banville; James R Burke; Kurt R Gregor; John F MacMaster; Alain Martel; Kim W McIntyre; Mark A Pattoli; F Christopher Zusi; Dolatrai Vyas
Journal:  Bioorg Med Chem Lett       Date:  2006-12-09       Impact factor: 2.823

5.  Synthesis and structure activity relationship studies of benzothieno[3,2-b]furan derivatives as a novel class of IKKbeta inhibitors.

Authors:  Hideyuki Sugiyama; Masato Yoshida; Kouji Mori; Tomohiro Kawamoto; Satoshi Sogabe; Terufumi Takagi; Hideyuki Oki; Toshimasa Tanaka; Hiroyuki Kimura; Yoshinori Ikeura
Journal:  Chem Pharm Bull (Tokyo)       Date:  2007-04       Impact factor: 1.645

6.  Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.

Authors:  Toshiki Murata; Mitsuyuki Shimada; Hiroshi Kadono; Sachiko Sakakibara; Takashi Yoshino; Tsutomu Masuda; Makoto Shimazaki; Takuya Shintani; Kinji Fuchikami; Kevin B Bacon; Karl B Ziegelbauer; Timothy B Lowinger
Journal:  Bioorg Med Chem Lett       Date:  2004-08-02       Impact factor: 2.823

7.  Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.

Authors:  Muttineni Ravikumar; S Pavan; Santhosh Bairy; A B Pramod; M Sumakanth; Madala Kishore; Tirunagaram Sumithra
Journal:  Chem Biol Drug Des       Date:  2008-05-21       Impact factor: 2.817

8.  An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice.

Authors:  J F MacMaster; D M Dambach; D B Lee; K K Berry; Y Qiu; F C Zusi; J R Burke
Journal:  Inflamm Res       Date:  2003-11-13       Impact factor: 4.575

9.  Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor.

Authors:  Róbert Kiss; Béla Noszál; Akos Rácz; András Falus; Dániel Eros; György M Keseru
Journal:  Eur J Med Chem       Date:  2007-08-06       Impact factor: 6.514

10.  The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases.

Authors:  John A Christopher; Barbara G Avitabile; Paul Bamborough; Aurelie C Champigny; Geoffrey J Cutler; Susan L Dyos; Ken G Grace; Jeffrey K Kerns; Jeremy D Kitson; Geoffrey W Mellor; James V Morey; Mary A Morse; Carolyn F O'Malley; Champa B Patel; Nicholas Probst; William Rumsey; Clive A Smith; Michael J Wilson
Journal:  Bioorg Med Chem Lett       Date:  2007-04-29       Impact factor: 2.823

View more
  2 in total

1.  IKKβ inhibitor identification: a multi-filter driven novel scaffold.

Authors:  Shanthi Nagarajan; Hyunah Choo; Yong Seo Cho; Kye Jung Shin; Kwang-Seok Oh; Byung Ho Lee; Ae Nim Pae
Journal:  BMC Bioinformatics       Date:  2010-10-15       Impact factor: 3.169

2.  Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution.

Authors:  Azizullo Musoev; Sodik Numonov; Zhuhong You; Hongwei Gao
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.